Will this blood test reveal my baby’s gender? Yes. With all this examining of chromosomes, NIPT can also tell you what sex your baby is. Make it clear to your practitioner whether or not you want this information revealed to you.

Limitations. While the results of these tests are highly accurate, discordant results, including inaccurate fetal sex prediction, may occur due to placental, maternal, or fetal mosaicism or neoplasm; vanishing twin; prior maternal organ transplant; or other causes.

Diagnostic Tests The sensitivity of eFTS for trisomy 21 is about 90% (specificity, about 95%). The sensitivity of MSS for trisomy 21 in the second trimester is 75% to 85% (specificity, 90% to 95%).

Using cutting-edge technology, these gender reveal tests are 99.9% accurate as early as 7 weeks pregnant—weeks earlier than a provider-ordered NIPT test. The best part? You can do this from the comfort of your home and find out baby gender without an ultrasound.

These screening tests–Harmony, Verifi, Panorama, and MaterniT21 are some examples–are touted by the labs who market them as more accurate than traditional screening like the Triple or Quad screening blood tests. The labs often cite data that show the tests to be 99% accurate.

CPM is the most common cause of false-positive NIPT results and occurs more frequently for trisomy 13 and monosomy X than it does for either trisomy 18 or trisomy 21 (3). To help address this problem, VCGS calculates a mosaicism score on every trisomic sample called.

Accuracy. With that being said, over 99% of ultrasounds performed between weeks 18 and 20 will make the correct determination. 4 It is only when it is performed before week 14 that the rate of accuracy can drop significantly.

While gender prediction is much more accurate during the 20-week ultrasound, there’s still a chance it can be wrong.

The MaterniT21 PLUS test methodology allows for rich, clinically relevant content that currently detects chromosomal abnormalities for chromosomes 21, 18, 13 in singleton and higher order multiple pregnancies, as well as fetal gender. Additionally, results are provided for fetal sex aneuploidies having 96,2% sensitivity : Turner Syndrome (45,XO)

The MaterniT21 PLUS test methodology allows for rich, clinically relevant content that currently detects chromosomal abnormalities for chromosomes 21, 18, 13 in singleton and higher order multiple pregnancies, as well as fetal gender.

As a noninvasive prenatal test, MaterniT 21 PLUS is different from both. It has higher detection rates than serum screening,1 and requires only a blood sample from the mother; amniocentesis requires withdrawing fluid from around the developing baby.

MaterniT21 PLUS is the first commercialized NIPT Test in the World, has been tested on thousands of women, and extracts the most reliable results. To date, the MaterniT21 PLUS laboratory-developed test is the most technologically advanced noninvasive prenatal test of its kind commercially available for detecting fetal chromosomal abnormalities.